09.05.2024 14:39:06 - dpa-AFX: *MERCK : PHASE 3 TRIAL OF KEYTRUDA PLUS CHEMOTHERAPY IN ENDOMETRIAL CANCER FAILS TO MEET MAIN GOAL

Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX
Name WKN Börse Kurs Datum/Zeit Diff. Diff. % Geld Brief Erster Schluss
Merck & Co A0YD8Q NYSE 127,280 27.06.24 20:29:57 -4,220 -3,21% 127,260 127,300 131,990 131,500

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH